Joewolf it seems that things can only go up - on current share...

First 5 Last

Share
Profile

Follow
sabine

18,778 Posts.

3952

01/09/17

09:26

Post #: 26920233
Share

Originally posted by joewolf ↑

I think you will find that the revaluation of Plant and equipment would require a lot of work. Plus the bank facilities are probably contingent upon them first seeing the financials. That's a very material audit issue.

So I expect that now that they have released they can give the bank the financials and get a letter saying that they are in compliance with the facility.

Really they made around 2c per share take out all the nonsense - the write downs write ups etc. The great takeaways for me:

Overall debt down - suspect they are selling some Plant and equipment that's why its held for sale. They are shrinking the business.

Writing off the tax loss well that's really just another adjustment that will come back into play if you continue to make money.

Getting back to basics will help. I really do think a CR would put this company back on the front foot. However I am sure the family don't want to put money back in...

I am happier with 100 million T/o and 5 million profit than 200million and a huge loss.

I will still hold...

Expand

Joewolf it seems that things can only go up - on current share price the company is worth the same amount as the equipment they have decided to sell .
Management seem to be really tightening their belts and turning things around but with CFO gone I think a big question is who is going to step into those shoes?

BYL Price at posting: 8.2¢ Sentiment: None Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

OJC

SPC to merge with Original Juice Co and Nature One Dairy

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals